


Status: Currently Official on 14-Feb-2025  
 Official Date: Official as of 01-May-2020  
 Document Type: USP Monographs  
 DocId: GUID-C93E13CA-8D13-4D2B-944D-E30DEE980A70\_5\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M32716\\_05\\_01](https://doi.org/10.31003/USPNF_M32716_05_01)  
 DOI Ref: h8da0

© 2025 USPC  
 Do not distribute

## Fenoldopam Mesylate



$C_{16}H_{16}ClNO_3 \cdot CH_3SO_3$  401.86

1H-3-Benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-, methanesulfonate (salt).

6-Chloro-2,3,4,5-tetrahydro-1-(*p*-hydroxyphenyl)-1H-3-benzazepine-7,8-diol methanesulfonate (salt) CAS RN®: 67227-57-0; UNII: HA3R0MY016.

» Fenoldopam Mesylate contains not less than 98.0 percent and not more than 102.0 percent of  $C_{16}H_{16}ClNO_3 \cdot CH_3SO_3$ , calculated on the anhydrous basis.

**Packaging and storage**—Preserve in tight containers, protected from moisture. Store at 25°, excursions permitted between 15° and 30°.

### USP REFERENCE STANDARDS (11)—

[USP Fenoldopam Mesylate RS](#)

[USP Fenoldopam Related Compound A RS](#)

6-Chloro-1-(4-hydroxyphenyl)-3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8-diol hydrochloride (*N*-methyl-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol hydrochloride).

$C_{17}H_{19}ClNO_3 \cdot HCl$  356.24

### Identification—

#### Change to read:

**A:** ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy: 197K](#) ▲ (CN 1-May-2020) .

**B:** The retention time of the major peak in the chromatogram of the *Assay preparation* corresponds to that in the chromatogram of the *Standard preparation*, as obtained in the *Assay*.

**WATER DETERMINATION, Method I (921)** : not more than 1.0%.

**RESIDUE ON IGNITION (281)**: not more than 0.1%.

### Limit of iodide—

**Mobile phase**—Prepare a filtered and degassed solution containing about 0.94 g of sodium bicarbonate, 0.952 g of sodium carbonate, 0.38 g of 4-cyanophenol, and 80 mL of acetonitrile in 4 L of water. Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

**Standard stock solution**—Transfer about 118.1 mg of sodium iodide, accurately weighed, to a 1000-mL volumetric flask. Dissolve in and dilute with water to volume, and mix to obtain a solution containing the equivalent of 100 µg of iodide per mL.

**Standard solutions**—Pipet 2.0 mL, 4.0 mL, 6.0 mL, and 8.0 mL of the *Standard stock solution* into separate 100-mL volumetric flasks, dilute with water to volume, and mix to obtain solutions having known concentrations of about 2 µg, 4 µg, 6 µg, and 8 µg of iodide per mL.

**Test solution**—Transfer about 300 mg of Fenoldopam Mesylate, accurately weighed, to a 100-mL volumetric flask. Dissolve in and dilute with water to volume, and mix.

**Chromatographic system**—The ion chromatograph is equipped with a conductivity detector, a 4-mm × 3.5-cm anion-exchange guard column, a 4-mm × 15-cm anion-exchange analytical column, and a micromembrane anion suppressor column. The flow rate is about 2.0 mL per minute. The regeneration solution for the suppressor column is a 0.050 M sulfuric acid solution, flowing at a rate of 5 mL per minute. Chromatograph the 6 µg per mL *Standard solution*, and record the peak responses as directed for *Procedure*: the relative standard deviation for replicate injections is not more than 5.0%.

**Procedure**—Separately inject equal volumes (about 100 µL) of each of the *Standard solutions* and the *Test solution* into the chromatograph, record the chromatograms, and measure the heights of peak responses. Plot the response of each of the *Standard solutions* versus the concentration, and draw the straight line best fitting the plotted points. From the graph so obtained, determine the quantity of iodide in the portion of Fenoldopam Mesylate taken: not more than 0.2% is found.

**Related compounds—**

*Buffer solution, System suitability stock solution, and System suitability solution*—Proceed as directed in the Assay.

*Solution A*—Use Mobile phase as prepared in the Assay.

*Solution B*—Use filtered and degassed methanol.

*Mobile phase*—Use variable mixtures of *Solution A* and *Solution B* as directed for *Chromatographic system*. Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

*Test solution*—Use the *System suitability stock solution*.

*Chromatographic system*—Proceed as directed in the Assay, except to program the chromatograph as follows.

Time (minutes)	Solution A (%)	Solution B (%)	Elution
0	100	0	equilibration
0–30	100	0	isocratic
30–60	100–70	0–30	linear gradient

*Procedure*—Inject a volume (about 20  $\mu$ L) of the *Test solution* into the chromatograph, record the chromatogram, and measure the peak responses. Calculate the percentage of each impurity in the portion of Fenoldopam Mesylate taken by the formula:

$$100(r_i/r_s)$$

in which  $r_i$  is the peak response for each impurity; and  $r_s$  is the sum of the responses of all the peaks: not more than 0.3% of fenoldopam related compound A is found; not more than 0.1% of any other individual impurity is found; and not more than 1.0% of total impurities is found.

**Limit of residual solvents—**

*Internal standard solution*—Prepare a solution, in organic-free water, containing 10 mg of *n*-butanol per mL. Transfer 100  $\mu$ L of this solution to a 10-mL volumetric flask, dilute with dimethylsulfoxide to volume, and mix.

*Standard solution*—Prepare a solution, in organic-free water, containing 10 mg each of *n*-propanol, isopropyl alcohol, and dimethylformamide per mL. Transfer 100  $\mu$ L of this solution to a 10-mL volumetric flask, dilute with *Internal standard solution* to volume, and mix.

*Test solution*—Transfer about 50 mg of Fenoldopam Mesylate, accurately weighed, to a 1-mL volumetric flask. Dilute with *Internal standard solution* to volume, and sonicate to dissolve completely.

*Chromatographic system* (see [CHROMATOGRAPHY \(621\)](#))—The gas chromatograph is equipped with a flame-ionization detector, a 0.32-mm  $\times$  30-m fused-silica capillary column coated with a 1.8- $\mu$ m film of stationary phase G43, and a split injection system. The carrier gas is helium, flowing at a rate of about 1 mL per minute through the column and a split ratio of about 50:1. The injection port and the detector temperatures are maintained at 140° and 260°, respectively. The column temperature is programmed as follows. It is maintained for 12 minutes at 40°, then increased at a rate of 8° per minute to 120°, held for 0.1 minute, then increased at a rate of 25° per minute to 180°, and maintained at that temperature for 8 minutes.

*Procedure*—Separately inject equal volumes (about 1  $\mu$ L) of the *Standard solution*, dimethylsulfoxide, and the *Test solution* into the chromatograph, record the chromatograms, and measure the peak areas. Identify, based on retention time, any peaks present in the chromatogram of the *Test solution*. Calculate the response factor,  $F$ , for each solvent in the *Standard solution* by the formula:

$$(W_R/W_I)(r_I/r_R)$$

in which  $W_R$  is the weight, in mg, of the solvent of interest;  $W_I$  is the weight, in mg, of the internal standard taken to prepare the *Internal standard solution*; and  $r_I$  and  $r_R$  are the peak responses for the internal standard and the solvent of interest, respectively, obtained from the *Standard solution*. Calculate the percentage, by weight, of each solvent found in the *Test solution* by the formula:

$$100FD(r_I/r_S)(W_I/W_D)$$

in which  $F$  is the average response factor for the solvent of interest obtained from all injections of the *Standard solution*;  $D$  is the dilution factor for the internal standard in the *Test solution* (i.e., 0.0001);  $r_I$  and  $r_S$  are the peak responses for the solvent of interest and the internal standard, respectively, obtained from the *Test solution*;  $W_I$  is the weight, in mg, of the internal standard taken to prepare the *Internal standard solution*; and  $W_D$  is the weight, in mg, of Fenoldopam Mesylate taken to prepare the *Test solution*: not more than 0.2% of total residual solvents is found.

**Assay—**

*Buffer solution*—Transfer about 16.33 g of monobasic potassium phosphate and 2 mL of triethylamine to a 2-L volumetric flask, and dissolve in 1800 mL of water. Adjust with phosphoric acid to a pH of 2.5, dilute with water to volume, and mix.

*Mobile phase*—Prepare a filtered and degassed mixture of *Buffer solution* and methanol (19:1). Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

*System suitability stock solution*—Transfer about 50 mg of Fenoldopam Mesylate, accurately weighed, to a 50-mL volumetric flask. With the aid of an ultrasonic bath, dissolve in and dilute with *Mobile phase* to volume, and mix.

**System suitability solution**—Transfer about 5 mg of [USP Fenoldopam Related Compound A RS](#), accurately weighed, to a 50-mL volumetric flask. Add about 25 mL of *Mobile phase*, and sonicate to dissolve. Add 5 mL of the *System suitability stock solution*, dilute with *Mobile phase* to volume, and mix.

**Standard preparation**—Dissolve an accurately weighed quantity of [USP Fenoldopam Mesylate RS](#) in *Mobile phase* to obtain a solution having a known concentration of about 0.1 mg per mL.

**Assay preparation**—Transfer 5.0 mL of the *System suitability stock solution*, accurately measured, to a 50-mL volumetric flask, dilute with *Mobile phase* to volume, and mix.

**Chromatographic system** (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with a 225-nm detector and a 3.9-mm × 30-cm column that contains packing L11. The flow rate is about 1.7 mL per minute. Chromatograph the *System suitability solution*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between fenoldopam and fenoldopam related compound A is not less than 1.5; the column efficiency is not less than 2000 theoretical plates; the tailing factor is not more than 1.3; and the relative standard deviation for replicate injections is not more than 2.0%.

**Procedure**—Separately inject equal volumes (about 20  $\mu$ L) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the peak responses. Calculate the quantity, in mg, of  $C_{16}H_{16}ClNO_3 \cdot CH_4SO_3$  in the portion of Fenoldopam Mesylate taken by the formula:

$$500C(r_U/r_S)$$

in which *C* is the concentration, in mg per mL, of [USP Fenoldopam Mesylate RS](#) in the *Standard preparation*; and  $r_U$  and  $r_S$  are the peak responses for fenoldopam obtained from the *Assay preparation* and the *Standard preparation*, respectively.

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
FENOLDOPAM MESYLATE	<a href="#">Documentary Standards Support</a>	SM22020 Small Molecules 2

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 29(5)

**Current DocID:** [GUID-C93E13CA-8D13-4D2B-944D-E30DEE980A70\\_5\\_en-US](#)

**DOI:** [https://doi.org/10.31003/USPNF\\_M32716\\_05\\_01](https://doi.org/10.31003/USPNF_M32716_05_01)

**DOI ref:** [h8dao](#)